-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ulotaront Hydrochloride in Psychosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ulotaront Hydrochloride in Psychosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ulotaront Hydrochloride in Psychosis Drug Details: Ulotaront hydrochloride (SEP-363856, SEP-856) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ulotaront Hydrochloride in Major Depressive Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ulotaront Hydrochloride in Major Depressive Disorder report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ulotaront Hydrochloride in Major Depressive Disorder Drug Details: Ulotaront hydrochloride...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ulotaront Hydrochloride in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ulotaront Hydrochloride in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ulotaront Hydrochloride in Parkinson's Disease Drug Details: Ulotaront hydrochloride (SEP-363856, SEP-856)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ulotaront Hydrochloride in Schizophrenia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ulotaront Hydrochloride in Schizophrenia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ulotaront Hydrochloride in Schizophrenia Drug Details: Ulotaront hydrochloride (SEP-363856, SEP-856) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ulotaront Hydrochloride in Generalized Anxiety Disorder (GAD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ulotaront Hydrochloride in Generalized Anxiety Disorder (GAD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ulotaront Hydrochloride in Generalized Anxiety Disorder (GAD) Drug Details:...
-
Product Insights
Seizures – Drugs In Development, 2023
Global Markets Direct’s, ‘Seizures - Drugs In Development, 2023’, provides an overview of the Seizures pipeline landscape. The report provides comprehensive information on the therapeutics under development for Seizures, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Company Profile
Sunovion Pharmaceuticals Inc – Company Profile
Sumitomo Pharma America Inc (Sumitomo Pharma), formerly Sunovion Pharmaceuticals Inc, is a research-based pharmaceutical company. It discovers, develops, and marketize therapeutic products that focus on the treatment of the central nervous system and respiratory disorders. Its major products include eslicarbazepine acetate tablets, lurasidone HCl tablets, relugolix, estradiol, and norethindrone acetate tablets, vibegron tablets, relugolix tablets, and allogeneic processed thymus tissue–agdc. The company’s product candidates are intended for the treatment of schizophrenia, neuropathic pain, bipolar depression, treatment-resistant depression, agitation in Alzheimer's...
Add to Basket -
Product Insights
Net Present Value Model: Ulotaront
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Ulotaront Drug Details Ulotaront (SEP-363856, SEP-856)...
-
Product Insights
Net Present Value Model: Edex
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Edex Drug Details Alprostadil (Edex, Viridal,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SEP-380135
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry SEP-380135 Drug Details SEP-380135 is under development for the treatment of agitation in Alzheimer's...